Last reviewed · How we verify
MenACWY-CRM (Menveo)
MenACWY-CRM (Menveo) is a Conjugate vaccine Biologic drug developed by GlaxoSmithKline. It is currently FDA-approved for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 2 months of age and older.
MenACWY-CRM is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by linking polysaccharide antigens to a carrier protein.
MenACWY-CRM is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by linking polysaccharide antigens to a carrier protein. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 2 months of age and older.
At a glance
| Generic name | MenACWY-CRM (Menveo) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W, and Y, each conjugated to a diphtheria toxoid carrier protein (CRM197). This conjugation enhances immunogenicity by promoting T-cell dependent B-cell responses, resulting in robust and sustained antibody production against these four serogroups. The induced antibodies provide protection against invasive meningococcal disease caused by these serogroups.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 2 months of age and older
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Headache
- Fatigue
- Fever
Key clinical trials
- Adolescent MenACWY Booster Study (PHASE4)
- Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination (PHASE3)
- Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study
- Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea (PHASE4)
- Understanding the Immune Response to Two Different Meningitis Vaccines (PHASE4)
- Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children (PHASE3)
- Safety Surveillance of MenACWY-CRM Vaccine in Children
- Safety of MenACWY-CRM Vaccination in Adolescents
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MenACWY-CRM (Menveo) CI brief — competitive landscape report
- MenACWY-CRM (Menveo) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about MenACWY-CRM (Menveo)
What is MenACWY-CRM (Menveo)?
How does MenACWY-CRM (Menveo) work?
What is MenACWY-CRM (Menveo) used for?
Who makes MenACWY-CRM (Menveo)?
What drug class is MenACWY-CRM (Menveo) in?
What development phase is MenACWY-CRM (Menveo) in?
What are the side effects of MenACWY-CRM (Menveo)?
Related
- Drug class: All Conjugate vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 2 months of age and older